#biotech

3개의 글

May 12, 2026

MDGL Madrigal Pharmaceuticals Stock Outlook 2026: Rezdiffra's First-Mover Lead vs. GLP-1 Competition

Madrigal Pharmaceuticals (MDGL) 2026 stock analysis: Rezdiffra revenue trajectory reaching $958M in FY2025 and $311M in Q1 2026, US payer coverage progress, GLP-1 competition dynamics, confirmatory trial risk, and acquisition thesis.

MDGL Madrigal Pharmaceuticals Rezdiffra

May 11, 2026

AZN AstraZeneca Stock Outlook 2026: Can the ADC Empire Sustain Its Momentum?

AstraZeneca (AZN) 2026 stock outlook covering Tagrisso, Enhertu, Datroway ADC pipeline, Farxiga CVRM growth, China VBP risk, and US Medicare price negotiation impact. Revenue data through Q1 2026.

AZN AstraZeneca biotech

May 11, 2026

NVO Novo Nordisk Stock Outlook 2026: GLP-1 Dominance Under Pressure

NVO Novo Nordisk stock outlook for 2026. Wegovy and Ozempic franchise vs Eli Lilly competition, CagriSema REDEFINE trial setback, IRA Medicare drug pricing risk, amycretin pipeline, and three-scenario valuation analysis for US investors.

NVO Novo Nordisk GLP-1